Anaptysbio Inc., of San Diego, initiated multiple ascending-dose cohorts in an ongoing double-blind, placebo-controlled phase I study of its anti-interleukin-33 antibody, ANB020, in healthy volunteers. Pending full results from the phase I trial, the company plans to develop ANB020 in patients with atopic dermatitis, peanut allergy and asthma. (See BioWorld Today, July 16, 2015.)